Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

ACADIA Pharmaceuticals Inc

ACAD ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$28.24

▼ -0.49%

Market Cap $4.87B · Vol 377.08K

Key Metrics

P/E Ratio

12.76

FWD: 35.66

Market Cap

$4.87B

Mid Cap

Div Yield

N/A

EPS Growth

-73.42%

YoY

RSI (14)

68.15

Momentum

Beta

0.86

vs Market

52W High

$29.85

5.39% below

52W Low

$19.69

43.42% above

Volume

377.08K

Avg 623.23K

P/B

3.71

Price-to-book

ROE

39.89%

Return on equity

Free Float

98.80%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, ACADIA Pharmaceuticals Inc (ACAD) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ACAD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.32%

+10.79%

+27.84%

+28.19%

YTD

+5.73%

+15.12%

-1.67%

+60.64%

Financials & Valuation

TTM · Annual

Total Revenue	$1.07B
Net Income	$391.00M
Revenue Growth (YoY)	+16.40%
Gross Margin	91.69%
Operating Margin	9.78%
Net Profit Margin	36.49%
ROE	39.89%
ROA · ROIC	10.09% · 39.89%

P/E Ratio	12.76
Forward P/E (FY1)	35.66
PEG Ratio	0.17
P/S	4.24
P/B	3.71
P/FCF	719.49
EPS Growth	-73.42%
Outstanding Shares	172.31M

Technical Indicators

50-Day SMA	$25.06
200-Day SMA	$23.98
RSI (14)	68.15
Beta	0.86
52-Week High	$29.85
52-Week Low	$19.69

Volume Today	377.08K
Avg Daily Volume (30D)	623.23K
Relative Volume	0.61x
Volatility (10D)	46.11
Volatility (30D)	33.95
Free Float	98.80%

Analyst Consensus

BUY

Current Price $28.24

Mean Target $33.63

52W Low$19.69 52W High$29.85

Current

Target

$19.69 $29.85

Current Analyst target

+19.09% upside potential · 21 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SB06N3

ISINUS0042251084

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.